000923168 000__ 03070cam\a2200445Ii\4500
000923168 001__ 923168
000923168 005__ 20230306151011.0
000923168 006__ m\\\\\o\\d\\\\\\\\
000923168 007__ cr\cn\nnnunnun
000923168 008__ 191031s2020\\\\sz\a\\\\ob\\\\001\0\eng\d
000923168 019__ $$a1129318135
000923168 020__ $$a9783030256104$$q(electronic book)
000923168 020__ $$a3030256103$$q(electronic book)
000923168 020__ $$z9783030256098
000923168 0247_ $$a10.1007/978-3-030-25610-4$$2doi
000923168 035__ $$aSP(OCoLC)on1125949135
000923168 035__ $$aSP(OCoLC)1125949135$$z(OCoLC)1129318135
000923168 040__ $$aGW5XE$$beng$$erda$$epn$$cGW5XE$$dUKMGB$$dUPM$$dOCLCF
000923168 049__ $$aISEA
000923168 050_4 $$aRC280.L9
000923168 08204 $$a616.99446$$223
000923168 24500 $$aNovel therapeutics for rare lymphomas /$$cChristopher Dittus, editor.
000923168 264_1 $$aCham, Switzerland :$$bSpringer,$$c[2020]
000923168 300__ $$a1 online resource (x, 253 pages) :$$billustrations.
000923168 336__ $$atext$$btxt$$2rdacontent
000923168 337__ $$acomputer$$bc$$2rdamedia
000923168 338__ $$aonline resource$$bcr$$2rdacarrier
000923168 347__ $$atext file$$bPDF$$2rda
000923168 504__ $$aIncludes bibliographical references and index.
000923168 5050_ $$aThe Hematopathology and Diagnostic Challenges of Rare Lymphomas -- Novel Therapeutics in the Management of Waldenstrom Macroglobulinemia -- Immunotherapy in Hodgkin Lymphoma and other CD30+ Lymphomas -- Chronic Lymphocytic Leukemia with Alterations in TP53 -- Mantel Cell Lymphoma -- Current and Emerging Treatment Strategies from Primary Mediastinal B-Cell Lymphoma -- Plasmablastic Lymphoma and Primary Effusion Lymphoma -- Novel Agents in Primary Central Nervous System Lymphoma -- Adult T-Cell Leukemia/Lymphoma -- Extranodal NK/T-Cell Lymphoma -- Anaplastic Large Cell Lymphoma -- Enteropathy-Associated T-Cell Lymphomas -- Hepatosplenic T-Cell Lymphoma -- Cutaneous T-Cell Lymphoma: Mycosis Fungoides and Sezary Syndrom.
000923168 506__ $$aAccess limited to authorized users.
000923168 520__ $$aThis comprehensive volume reviews the clinical presentation, diagnosis, and treatment approach to rare lymphomas. There is particular emphasis placed on new diagnostic approaches, novel chemotherapy combinations, and treatment modalities with novel therapeutics. It highlights research advances in a group of diseases that are often overlooked, and serves as a single repository of information on the most recent advances in targeted small molecule inhibitors, monoclonal antibodies, immunotherapy, and CAR-T therapy as they pertain to rare types of lymphoma. Written for practicing oncologists, hematologists, fellows, and residents, Novel Therapeutics for Rare Lymphomas covers rare subtypes of lymphoma, including indolent and aggressive T-cell lymphomas and B-cell lymphomas.
000923168 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed October 31, 2019).
000923168 650_0 $$aLymphomas$$xTreatment.
000923168 7001_ $$aDittus, Christopher,$$eeditor.
000923168 77608 $$iPrint version: $$z9783030256098
000923168 852__ $$bebk
000923168 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-030-25610-4$$zOnline Access$$91397441.1
000923168 909CO $$ooai:library.usi.edu:923168$$pGLOBAL_SET
000923168 980__ $$aEBOOK
000923168 980__ $$aBIB
000923168 982__ $$aEbook
000923168 983__ $$aOnline
000923168 994__ $$a92$$bISE